Marek Kasznicki

818 total citations
18 papers, 564 citations indexed

About

Marek Kasznicki is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Marek Kasznicki has authored 18 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 14 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Marek Kasznicki's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (14 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Marek Kasznicki is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (14 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Marek Kasznicki collaborates with scholars based in Poland, United States and Czechia. Marek Kasznicki's co-authors include Tadeusz Robak, Jerzy Z. Błoński, Joanna Góra‐Tybor, Jadwiga Dwilewicz‐Trojaczek, L Konopka, Anna Dmoszyńska, B. Ceglarek, Piotr Smolewski, Andrzej Hellmann and W. Nowak and has published in prestigious journals such as Blood, European Journal of Cancer and British Journal of Haematology.

In The Last Decade

Marek Kasznicki

18 papers receiving 547 citations

Peers

Marek Kasznicki

GENET

PFM

IMMUN

ONCOL

HEMAT

Jay Schachner United States

Martin Cremer Germany

Iris de Weerdt Netherlands

Sara Raponi Italy

Kenneth A. Foon United States

Luca Vincenzo Cappelli Italy

Alexandra Schrader Germany

Matthew J. Ahearne United Kingdom

Véronique Salaün France

Priscilla Do United States

Jay Schachner United States

Marek Kasznicki

343 ×0.7

GENET

206 ×0.5

PFM

163 ×0.9

IMMUN

88 ×0.9

ONCOL

141 ×1.7

HEMAT

Citations per year, relative to Marek Kasznicki Marek Kasznicki (= 1×) peers Jay Schachner

Countries citing papers authored by Marek Kasznicki

Since Specialization

Citations

This map shows the geographic impact of Marek Kasznicki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Kasznicki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Kasznicki more than expected).

Fields of papers citing papers by Marek Kasznicki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marek Kasznicki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Kasznicki. The network helps show where Marek Kasznicki may publish in the future.

Co-authorship network of co-authors of Marek Kasznicki

This figure shows the co-authorship network connecting the top 25 collaborators of Marek Kasznicki. A scholar is included among the top collaborators of Marek Kasznicki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marek Kasznicki. Marek Kasznicki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Robak, Tadeusz, Anna Korycka, Marek Kasznicki, Agata Wrzesień‐Kuś, & Piotr Smolewski. (2005). Purine Nucleoside Analogues for the Treatment of Hematological Malignancies: Pharmacology and Clinical Applications. Current Cancer Drug Targets. 5(6). 421–444. 57 indexed citations

Robak, Tadeusz, Anna Szmigielska‐Kapłon, Jerzy Z. Błoński, Marek Kasznicki, & Krzysztof Chojnowski. (2005). Activity of Cladribine Combined with Etoposide in Heavily Pretreated Patients with Indolent Lymphoid Malignancies. Chemotherapy. 51(5). 247–251. 7 indexed citations

Robak, Tadeusz, Jerzy Z. Błoński, Marek Kasznicki, et al.. (2005). Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).. PubMed. 11(10). PI71–9. 15 indexed citations

Robak, Tadeusz, Piotr Smolewski, H Urbańska-Ryś, et al.. (2004). Rituximab Followed by Cladribine in the Treatment of Heavily Pretreated Patients with Indolent Lymphoid Malignancies. Leukemia & lymphoma. 45(5). 937–944. 26 indexed citations

Robak, Tadeusz, Jerzy Z. Błoński, Joanna Góra‐Tybor, et al.. (2004). Cladribine Alone or in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone as First Line Treatment in Chronic Lymphocytic Leukemia: An Early Report of Prospective Randomized Study.. Blood. 104(11). 337–337. 8 indexed citations

Robak, Tadeusz, Marek Kasznicki, Joanna Góra‐Tybor, et al.. (2004). Randomized Comparison of Weekly Administration and Daily Courses of Cladribine in Patients with Hairy Cell Leukemia - Updated Results.. Blood. 104(11). 3478–3478. 5 indexed citations

Robak, Tadeusz, Jerzy Z. Błoński, Joanna Góra‐Tybor, et al.. (2003). Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. European Journal of Cancer. 40(3). 383–389. 55 indexed citations

Robak, Tadeusz, Marek Kasznicki, Joanna Góra‐Tybor, et al.. (2002). Re‐treatment with cladribine‐based regimens in relapsed patients with B‐cell chronic lymphocytic leukemia. European Journal Of Haematology. 69(1). 27–36. 10 indexed citations

Robak, Tadeusz & Marek Kasznicki. (2002). Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia. 16(6). 1015–1027. 70 indexed citations

10.

Robak, Tadeusz, Jerzy Z. Błoński, Marek Kasznicki, et al.. (2002). Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. The Hematology Journal. 3(5). 244–250. 38 indexed citations

11.

Robak, Tadeusz, Marek Kasznicki, Joanna Góra‐Tybor, et al.. (2001). Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia. 15(10). 1510–1516. 32 indexed citations

12.

Robak, Tadeusz, Marek Kasznicki, Jacek Bartkowiak, et al.. (2001). Richter's Syndrome Following Cladribine Therapy for Chronic Lymphocytic Leukemia First Manifested as Pathologic Fracture of the Femur. Leukemia & lymphoma. 42(4). 789–796. 14 indexed citations

13.

Robak, Tadeusz, Jerzy Z. Błoński, & Marek Kasznicki. (2001). Does Intensive Treatment with High Dose Chlorambucil and Prednisone as First Line and Cladribine as Second Line Influence the Survival of the Patients with Chronic Lymphocytic Leukemia?. Leukemia & lymphoma. 41(5-6). 545–557. 8 indexed citations

14.

Robak, Tadeusz, Joanna Góra‐Tybor, Ewa Lech‐Marańda, Jerzy Z. Błoński, & Marek Kasznicki. (2001). Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre‐treated patients with advanced indolent lymphoid malignancies. European Journal Of Haematology. 66(3). 188–194. 28 indexed citations

15.

Robak, Tadeusz, Marek Kasznicki, Jerzy Z. Błoński, Anna Dmoszyńska, & A B Skotnicki. (2001). CORRESPONDENCE. British Journal of Haematology. 112(4). 1083–1085. 4 indexed citations

16.

Robak, Tadeusz, Jerzy Z. Błoński, Marek Kasznicki, et al.. (2000). Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.. Blood. 96(8). 2723–9. 185 indexed citations

17.

Robak, Tadeusz, et al.. (1999). Atypical Chronic Myelogenous Leukemia Following Immunosuppressive Therapy for Severe Aplastic Anemia. Leukemia & lymphoma. 35(1-2). 193–199. 1 indexed citations

18.

Robak, Tadeusz, et al.. (1993). [Therapeutic problems during pregnancy and delivery in two women with aplastic anemia].. PubMed. 24(2). 183–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact